JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorGezondheidszorg

28.92 10.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

26.1

Max

29.24

Belangrijke statistieken
By Trading Economics
Inkomsten	-5.8M 40M
Verkoop	16M 200M
K/W Sectorgemiddelde	8.367 37.461
EPS	0.92
Winstmarge	19.839
Werknemers	268
EBITDA	3M 59M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+70.34% upside

Dividenden
By Dow Jones
Volgende Winsten	28 okt 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-544M 1.5B
Vorige openingsprijs	18.83
Vorige sluitingsprijs	28.92

Nieuwssentiment

By Acuity

34%

66%

108 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 okt 2025, 22:47 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 okt 2025, 22:13 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 okt 2025, 21:20 UTC

Winsten

Correction to IBM 3Q Sales Jump Article

22 okt 2025, 20:57 UTC

Winsten

SAP Posts Higher 3Q Revenue, Operating Profit

22 okt 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 okt 2025, 23:46 UTC

Marktinformatie

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 okt 2025, 23:41 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:38 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:15 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 okt 2025, 22:28 UTC

Marktinformatie

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 okt 2025, 22:02 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 okt 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 okt 2025, 21:58 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 okt 2025, 21:57 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 okt 2025, 21:56 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 okt 2025, 21:47 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 okt 2025, 21:46 UTC

Acquisities, Fusies, Overnames

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 okt 2025, 21:28 UTC

Marktinformatie

Winsten

Correction to Alcoa Tariff Market Talk

22 okt 2025, 21:25 UTC

Winsten

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 okt 2025, 21:17 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 okt 2025, 21:09 UTC

Marktinformatie

Winsten

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 okt 2025, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

22 okt 2025, 20:59 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 20:51 UTC

Winsten

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 okt 2025, 20:44 UTC

Winsten

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

70.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44.56 USD 70.34%

Hoogste 62 USD

Laagste 31 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

108 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.